South Korea · Delayed Price · Currency is KRW L&C BIO Co.,LTD Statistics
Total Valuation
L&C BIO Co.,LTD has a market cap or net worth of KRW 1.34 trillion. The enterprise value is 1.39 trillion.
| Market Cap | 1.34T |
| Enterprise Value | 1.39T |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
L&C BIO Co.,LTD has 24.62 million shares outstanding. The number of shares has increased by 2.88% in one year.
| Current Share Class | 24.62M |
| Shares Outstanding | 24.62M |
| Shares Change (YoY) | +2.88% |
| Shares Change (QoQ) | +4.26% |
| Owned by Insiders (%) | 26.34% |
| Owned by Institutions (%) | 11.86% |
| Float | 17.00M |
Valuation Ratios
The trailing PE ratio is 10.89.
| PE Ratio | 10.89 |
| Forward PE | n/a |
| PS Ratio | 17.59 |
| PB Ratio | 4.13 |
| P/TBV Ratio | 11.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 1,707.82 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 245.51, with an EV/FCF ratio of -241.06.
| EV / Earnings | 11.20 |
| EV / Sales | 18.32 |
| EV / EBITDA | 245.51 |
| EV / EBIT | n/a |
| EV / FCF | -241.06 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.04 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 18.44 |
| Debt / FCF | -18.11 |
| Interest Coverage | -0.61 |
Financial Efficiency
Return on equity (ROE) is 51.63% and return on invested capital (ROIC) is -0.37%.
| Return on Equity (ROE) | 51.63% |
| Return on Assets (ROA) | -0.33% |
| Return on Invested Capital (ROIC) | -0.37% |
| Return on Capital Employed (ROCE) | -0.55% |
| Revenue Per Employee | 535.05M |
| Profits Per Employee | 875.27M |
| Employee Count | 142 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 0.82 |
Taxes
| Income Tax | -6.14B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +205.92% in the last 52 weeks. The beta is 0.60, so L&C BIO Co.,LTD's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +205.92% |
| 50-Day Moving Average | 36,913.00 |
| 200-Day Moving Average | 26,895.60 |
| Relative Strength Index (RSI) | 63.43 |
| Average Volume (20 Days) | 1,683,351 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&C BIO Co.,LTD had revenue of KRW 75.98 billion and earned 124.29 billion in profits. Earnings per share was 4,923.41.
| Revenue | 75.98B |
| Gross Profit | 37.34B |
| Operating Income | -1.96B |
| Pretax Income | 118.46B |
| Net Income | 124.29B |
| EBITDA | 5.67B |
| EBIT | -1.96B |
| Earnings Per Share (EPS) | 4,923.41 |
Balance Sheet
The company has 59.87 billion in cash and 104.54 billion in debt, giving a net cash position of -44.67 billion or -1,814.30 per share.
| Cash & Cash Equivalents | 59.87B |
| Total Debt | 104.54B |
| Net Cash | -44.67B |
| Net Cash Per Share | -1,814.30 |
| Equity (Book Value) | 323.52B |
| Book Value Per Share | 12,720.49 |
| Working Capital | 5.77B |
Cash Flow
In the last 12 months, operating cash flow was 782.75 million and capital expenditures -6.56 billion, giving a free cash flow of -5.77 billion.
| Operating Cash Flow | 782.75M |
| Capital Expenditures | -6.56B |
| Free Cash Flow | -5.77B |
| FCF Per Share | -234.53 |
Margins
Gross margin is 49.14%, with operating and profit margins of -2.58% and 163.59%.
| Gross Margin | 49.14% |
| Operating Margin | -2.58% |
| Pretax Margin | 155.92% |
| Profit Margin | 163.59% |
| EBITDA Margin | 7.46% |
| EBIT Margin | -2.58% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.08%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.08% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.90% |
| Buyback Yield | -2.88% |
| Shareholder Yield | -2.80% |
| Earnings Yield | 9.30% |
| FCF Yield | -0.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 12, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Oct 12, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
L&C BIO Co.,LTD has an Altman Z-Score of 2.58 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.58 |
| Piotroski F-Score | 2 |